GLP-1 has turned peptides from a niche modality into an industrial commodity, pushing the world's leading CDMOs into a capacity arms race measured in tonnes and hundreds of thousands of litres. This piece maps demand-side explosion, a six-player expansion table, the utilization red light and structural mismatch, and argues the battle line has moved from reactor volume to integrated one-stop, globally compliant delivery.

In three years, GLP-1 therapies have turned the peptide modality from a niche into an industrial commodity. Exponential demand is forcing the world's leading CDMOs into a capacity arms race measured in tonnes and hundreds of thousands of litres. But as expansion becomes consensus, a real dividing line has emerged: the contest is no longer just about reactor volume, but about who can stitch long-chain complex peptides, high-end modifications and globally compliant delivery into one integrated loop.

1. Demand: GLP-1 turns peptides into an industrial commodity

The change in demand magnitude is the starting point. Semaglutide plus tirzepatide generated roughly USD 8.7 bn in 2025, about 67% of the global peptide therapeutics market, and the category is set to top USD 100 bn in 2026. More importantly, the growth engine is spilling outward: as of June 2026 there were 212 peptide candidates in clinical development (168 in 2023), with oncology (78) overtaking metabolic (54) - driven by peptide-drug conjugates (PDCs) and neoantigen cancer vaccines. Peptides are moving from a single metabolic pole to a multipolar field, meaning CDMOs must serve an entire pipeline rather than a handful of blockbusters.

2. The capacity arms race: a six-player expansion table

Once demand was confirmed, the leaders unanimously bought certainty with capex. Laid side by side, the 2026 capacity moves of the major players reveal one clear thread: China expands aggressively on speed and cost, while the West hedges supply-chain risk with onshore capacity.

Table 1 Major peptide CDMO capacity moves in 2026 (cxdmo.com)
PlayerCapacity (existing/planned)Expansion moveSignal
WuXi AppTec TIDES130 kL SPPS2025 revenue RMB 11.37 bn (+96%); 2026 guided >RMB 15 bn (+40%)Serves 24 GLP-1 programs (15 in Ph II/III)
Asymchem45 kL → 69 kLTianjin site adds RMB 2 bnRapid commercial peptide scale-up
Bachem (CH)Building K tonnage ramp 20262026 capex >CHF 400 m; revenue guide +35-45%Peptide + oligonucleotide dual engine
CordenPharmaColorado >EUR 1 bn expansionAcquired AmbioPharm, adding US/China capacityEmphasizes US onshore peptide mfg
PolyPeptideTo be acquired by Samsung Biologics for USD 1.78 bnGlobal capacity consolidation acceleratingWestern leader being folded in
Lilly / Novo (in-house)Lilly IN USD 1 bn + AL USD 6 bn; Novo ~130 kLSponsors repatriate core pipelinesCrowds out some outsourced orders
Capacity metrics mix SPPS volume, plant investment and internal API networks and are not strictly comparable; figures are public disclosures or industry reporting.

3. The utilization red light: >85% industry-wide, but structurally mismatched

The more aggressive the expansion, the louder the alarm. In a recent interview CordenPharma's CEO noted peptide-CDMO utilization exceeds 85% across major providers and over 65% of pharma companies outsource peptide manufacturing - both a proof of strength and a precursor to oversupply. The sharper issue is structural mismatch: global SPPS peptide API capacity is about 8.2 tonnes/year, with Novo and Lilly alone consuming ~40% for GLP-1; yet China's planned GLP-1 peptide API capacity has reached 33-40 tonnes against ~50 tonnes of global core demand in 2030. The imbalance is already pressuring price: semaglutide API quotes fell from ~USD 900/g to USD 90-160/g, with a further 20%-30% drop expected. The result is utilization below 60% at smaller CDMOs (vs ~85% at leaders), and an estimated 30%-40% industry cull rate through 2026-2028.

4. The dividing line: from reactor volume to one-stop + global compliance

As bare capacity heads toward surplus, the competitive focus has shifted from reactor volume to full one-stop capability. The gap between domestic and overseas players is narrowing: Chinese CDMOs, leveraging engineer dividends and capex appetite, show strong competitiveness on speed and cost, with WuXi AppTec and Asymchem both building integrated loops from pre-clinical CMC to commercial drug product (lyophilization, prefilled syringes) to handle the rapid R-to-commercial transition of GLP-1 blockbusters. Upstream localization also hardens the cost edge - in resins, protecting groups and chromatography media, Nanomicro, Highfine and others are accelerating the substitution of overseas giants like Merck. Meanwhile, Western reshoring of critical APIs (CordenPharma stresses US onshore manufacturing), layered with Section 232 tariffs and regulatory scrutiny, forces exporters to face a dual compliance-policy squeeze: whoever assembles the most complete globally compliant, one-stop capability survives the coming shakeout.

5. Risks and outlook: oversupply and geopolitics, a double test

For all the strength, mid-term risks are real. First, structural oversupply: after Bachem and CordenPharma's aggressive builds, a marginal GLP-1 slowdown or non-core peptide pipeline failures could trigger near-term underutilization and price wars. Second, technology disruption: oral GLP-1 (e.g. Lilly's orforglipron) turns 'peptide' into 'small molecule', loosening the logic of SPPS dependence over the long run; continuous flow, enzymatic synthesis and AI-assisted conjugation/purification optimization are morphing from industrialization bottlenecks of long-chain, cyclic and complex-modified peptides into the moats of leading CDMOs. 2026 is the pivotal year when peptide CDMOs move from 'follow-on R&D' to 'absorbing tonnage-scale commercialization' - the GLP-1 halo remains, but only those mastering complex modifications, globally compliant capacity and one-stop service will survive the cycle.

Peptide CDMO competition has shifted from the quantity of capacity to an integrated contest of long-chain complex peptides + high-end modification + globally compliant delivery; generic SPPS capacity is turning from a scarce asset into capacity awaiting clearance.

cxdmo.com Insight

FAQ

Capacity looks huge, so why the 'red light'?

Because of structural mismatch: China's planned GLP-1 peptide API capacity already reaches 33-40 tonnes/year against ~50 tonnes of global core demand in 2030, and semaglutide's China compound patent expired in March 2026 with a wave of generics, pushing API quotes from ~USD 900/g down to USD 90-160/g. What is truly scarce is compliant capacity for long-chain complex peptides, high-end modifications and oral/continuous-flow processes - not bare capacity.

How high is global peptide-CDMO utilization really?

CordenPharma's CEO recently disclosed utilization above 85% across major providers and over 65% of pharma outsourcing peptide manufacturing; but the split is stark - leaders ~85%, smaller CDMOs below 60%, with the cull pressure concentrated in the latter.

Will oral GLP-1 disrupt peptide CDMOs?

A long-run variable, not a near-term shock. Lilly's orforglipron turns 'peptide' into 'small molecule', loosening SPPS dependence; yet oral formats, continuous flow, enzymatic synthesis and AI-assisted process optimization are becoming the new moats that replace generic capacity at the leaders.

Which Chinese players benefit most?

The leaders with an integrated loop and globally compliant capacity: WuXi AppTec TIDES (130 kL, 2026 revenue guided >RMB 15 bn) and Asymchem (45→69 kL, RMB 2 bn Tianjin) lead; upstream, Nanomicro and Highfine harden the cost edge via resin/protecting-group/media substitution. The key is complex-modification and compliant-delivery capability, not capacity size.

This article is compiled from public reporting. Original source: Compiled from Digital Medicine Network, CordenPharma CEO interview, Jiemian, WuXi AppTec 2026 earnings call, and Bachem / PolyPeptide / Samsung Biologics public disclosures · For industry reference only; not investment advice.